Prestige Consumer Healthcare Inc. PBH
Analyst Ratings
- Consensus
- Hold — 1 Buy · 2 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $69.00 (+34.3% upside)
Key Stats
- Today's Range
- $50.35 – $52.00
- 50-Day Range
- $44.89 – $55.99
- 52-Week Range
- $42.62 – $78.97
- Volume
- 487K shs
- Average Volume
- 536K shs
- Market Cap
- $2.48 billion
- P/E Ratio
- 14.39
- Dividend Yield
- —
Valuation
- P/E Ratio
- 14.39
- Price / Book
- 1.29
- Price / Sales
- 2.24
Short Interest
- Short Interest
- 14.86%
- Days to Cover
- 17.88
Financials (TTM)
- Revenue
- $1.10 billion
- Net Income
- $172.01 million
- Net Margin
- 15.57%
- Return on Equity
- 8.97%
- Debt-to-Equity
- —
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Related Stocks
Compare head-to-head: PBH vs LLY·PBH vs JNJ·PBH vs ABBV·PBH vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.